Elanco Animal Health Acquires Boehringer Ingelheim Vetmedica’s U.S. Feline, Canine and Rabies Vaccines Portfolio
NEW YORK – Paul Hastings LLP, a leading global law firm, announced today that the firm represented Elanco US Inc., a division of Eli Lilly and Company, in the completion of its approximately $885 million acquisition of Boehringer Ingelheim Vetmedica’s U.S. feline, canine and rabies vaccines portfolio, along with a fully integrated manufacturing and R&D site and several pipeline assets.
The acquisition diversifies Elanco’s U.S. companion animal portfolio by adding vaccines for a range of common concerns, including bordetella, Lyme disease, feline leukemia, rabies, and parvovirus.
The Paul Hastings team was led by Mergers and Acquisitions partner
At Paul Hastings, our purpose is clear — to help our clients and people navigate new paths to growth. With a strong presence throughout Asia, Europe, Latin America, and the U.S., Paul Hastings is recognized as one of the world’s most innovative global law firms.